Analytical Data
-
Gene name
inaX
- Application
-
Alternative Names
/
-
Species
Xanthomonas campestris pv. translucens
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P18127
-
Expression Region
1412-1567aa
-
Molecular Weight
22.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of recombinant proteins, particularly in the context of insulin-like growth factor (IGF) and its analogs, has garnered significant attention in the field of molecular biology and biotechnology. One notable product is the inaX recombinant protein, which is engineered to enhance therapeutic benefits while minimizing side effects associated with traditional treatments. Advances in genetic engineering have allowed scientists to manipulate the DNA sequences encoding these proteins, leading to increased expression levels and improved functionality. Research has shown that inaX may play a pivotal role in biological processes such as cell growth, differentiation, and metabolism. The recombinant production methods enable large-scale synthesis of inaX, facilitating studies on its mechanism of action and potential applications in regenerative medicine and cancer therapeutics. Moreover, despite the promise shown by recombinant proteins, challenges regarding their stability, scalability, and post-translational modifications remain, necessitating ongoing research. The exploration of inaX and similar proteins not only broadens the understanding of IGF-related pathways but also holds the potential for innovative treatments in various diseases, underscoring the importance of continued investigations in this promising area of biotechnology.
